The Korean Journal of Urological Oncology10.22465/kjuo.2021.19.2.1092021192109-116Predictive Factors of De Novo Overactive Bladder After Radical Prostatectomy in Patients With Clinically Localized Prostate Cancer: A Prospective Observational StudyJun Nyung Lee, Sang Won Kim, Kyeong-Hyeon Byeon, Jae-Wook Chung, Yun-Sok Ha, Seock Hwan Choi, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon,,
Prostate International10.1016/j.prnil.2017.05.0042018617-11Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)Satoru Ueno, Yasuhide Kitagawa, Mizuki Onozawa, Shiro Hinotsu, Hideyuki Akaza, Atsushi Mizokami, Mikio Namiki,
International Journal of Urology10.1111/j.1442-2042.2010.02577.x2010178725-726Editorial Comment to Feasibility of antegrade radical prostatectomy for clinically locally advanced prostate cancer: A comparative study with clinically localized diseaseShigeto Ishidoya,
BJU International10.1046/j.1464-410x.2003.04269.x200392119-23Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomyD.W. Brandli, M.O. Koch, R.S. Foster, R. Bihrle, T.A. Gardner,
Cancer10.1002/(sici)1097-0142(19960701)78:1<181::aid-cncr28>;2-v1996781181-181aSurvival after radical retropubic prostatectomy of men and clinically localized high grade carcinoma of the prostateIan M. Thompson;2-V,;2-V
Urology10.1016/s0090-4295(96)00167-71996482249-260Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancerPatrick Kupelian, Jerald Katcher, Howard Levin, Craig Zippe, Eric Klein,
OncoTargets and Therapy10.2147/ott.s441442013725Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patientsJinan Liu, Shi, Oliver Sartor, Richard Culbertson
BJU International10.1046/j.1464-410x.2003.t01-4-04488.x2003927824-824Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomyE.Z. Neulander, G.F. Greene, Z. Wajsman,
Prostate International10.1016/j.prnil.2017.01.00120175113-16Safety and feasibility of robot-assisted radical prostatectomy for clinically localized prostate cancer in elderly Japanese patientsMasatomo Nishikawa, Hiromitsu Watanabe, Tomofumi Kurahashi,
BJU International10.1111/j.1464-410x.2011.10623.x2011109121824-1830Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?Martin Boettcher, Angelika Haselhuhn, Gerhard Jakse, Bernhard Brehmer, Ruth Kirschner-Hermanns,